NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









TRexBio

TRexBio

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://trex.bio/

Last Round

Series B

Extension

Jan 27, 2026

Total Funding Raised

$219M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

TRexBio is a biotechnology company that develops immunoregulatory medicines by mapping human tissue regulatory T cell behavior to disease processes to identify novel therapeutic targets.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

regulatory T cellsTregstissue-targeted therapeuticsimmune-mediated diseasesTNFR2 agonistCD30 agonistbiotech drug discoverycomputational biologyin-silico drug discoveryimmune homeostasisclinical-stage biotechdrug development pipelineprecision immunologyatopic dermatitis treatmentpharma partnering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

TRexBio Comps

Public and private peers based on sector, stage, and business model.

TRexBio comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

TRexBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionJan 27, 2026
Series BNov 13, 2024
Series A ExtensionMar 8, 2022
Series AJun 22, 2021

Key People

Founding team and executive leadership

Johnston Erwin

Chief Executive Officer

Executive Team

Brandon H.

Chief Financial Officer

Executive Team

TRexBio Investors

Notable investors and investment history

TRexBio investors
InvestorRounds
Avego ManagementSeries B, Series B Extension
Janus Henderson GroupSeries B Extension
Agent CapitalSeries B
Balyasny Asset Management L.P.Series B Extension
SV Health InvestorsSeries B, Series A, Series A Extension, Series B Extension, Seed
Alexandria Venture InvestmentsSeries B, Series A, Series A Extension, Series B Extension
Pfizer VenturesSeries B, Series A, Series A Extension, Series B Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 27, 2026

    $50M Series B Extension round completed.

  • Nov 13, 2024

    $84M round led by Delos Capital Partners.

TRexBio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

TRexBio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about TRexBio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range61
Year Founded2018
Last FundingJan 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.